Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression.

Kim YH, Kim JH, Choi YW, Lim SK, Yim H, Kang SY, Chung YS, Lee GY, Park TJ.

Exp Mol Pathol. 2013 Apr;94(2):360-5. doi: 10.1016/j.yexmp.2012.12.002. Epub 2012 Dec 28.

PMID:
23276718
3.

Microcysts and breast cancer: a study of biological markers in archival biopsy material.

Tran DD, Lawson JS.

Breast Cancer Res Treat. 2002 Oct;75(3):213-20.

PMID:
12353810
4.

Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.

Hussein MR, Abd-Elwahed SR, Abdulwahed AR.

Cell Biol Int. 2008 Jun;32(6):698-707. doi: 10.1016/j.cellbi.2008.01.007. Epub 2008 Jan 25.

PMID:
18296077
5.

The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.

Di Modugno F, Mottolese M, Di Benedetto A, Conidi A, Novelli F, Perracchio L, Venturo I, Botti C, Jager E, Santoni A, Natali PG, Nisticò P.

Clin Cancer Res. 2006 Mar 1;12(5):1470-8.

6.

CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.

Bircan S, Kapucuoglu N, Baspinar S, Inan G, Candir O.

Pathol Res Pract. 2006;202(8):569-76. Epub 2006 Jul 7.

PMID:
16828238
7.

EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.

Lebeau A, Unholzer A, Amann G, Kronawitter M, Bauerfeind I, Sendelhofert A, Iff A, Löhrs U.

Breast Cancer Res Treat. 2003 May;79(2):187-98.

PMID:
12825853
8.

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.

9.

Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.

Lee A, Park WC, Yim HW, Lee MA, Park G, Lee KY.

Jpn J Clin Oncol. 2007 Sep;37(9):708-14.

PMID:
17940078
10.

Matrix metalloproteinase-9 as a potential tumor marker in breast cancer.

Nanda DP, Sil H, Moulik S, Biswas J, Mandal SS, Chatterjee A.

J Environ Pathol Toxicol Oncol. 2013;32(2):115-29.

PMID:
24099425
11.

Expression of manganese superoxide dismutase in patients with breast cancer.

Tsai SM, Hou MF, Wu SH, Hu BW, Yang SF, Chen WT, Chai CY, Ma H, Tsai LY.

Kaohsiung J Med Sci. 2011 May;27(5):167-72. doi: 10.1016/j.kjms.2010.11.003. Epub 2011 Mar 21.

13.

Nm-23, c-erbB-2, and progesterone receptor expression in invasive breast cancer: correlation with clinicopathologic parameters.

Nakopoulou LL, Tsitsimelis D, Lazaris AC, Tzonou A, Gakiopoulou H, Dicoglou CC, Davaris PS.

Cancer Detect Prev. 1999;23(4):297-308.

PMID:
10403901
14.
15.

Gankyrin is essential for hypoxia enhanced metastatic potential in breast cancer cells.

Gao L, Xie H, Dong L, Zou J, Fu J, Gao X, Ou L, Xiang S, Song H.

Mol Med Rep. 2014 Mar;9(3):1032-6. doi: 10.3892/mmr.2013.1860. Epub 2013 Dec 12.

PMID:
24337075
16.
17.

The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.

Salvucci O, Bouchard A, Baccarelli A, Deschênes J, Sauter G, Simon R, Bianchi R, Basik M.

Breast Cancer Res Treat. 2006 Jun;97(3):275-83. Epub 2005 Dec 13.

PMID:
16344916
18.

Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells.

Sun W, Ding J, Wu K, Ning BF, Wen W, Sun HY, Han T, Huang L, Dong LW, Yang W, Deng X, Li Z, Wu MC, Feng GS, Xie WF, Wang HY.

Hepatology. 2011 Oct;54(4):1259-72. doi: 10.1002/hep.24530.

PMID:
21735473
19.

Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.

D'Andrea MR, Limiti MR, Bari M, Zambenedetti P, Montagutti A, Ricci F, Pappagallo GL, Sartori D, Vinante O, Mingazzini PL.

Breast Cancer Res Treat. 2007 Mar;101(3):279-84. Epub 2006 Jul 12.

PMID:
16835704
20.

Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.

Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ.

Clin Cancer Res. 2005 Mar 15;11(6):2163-8.

Supplemental Content

Support Center